Status:
COMPLETED
Contribution of Inflammation and Neuronal Integrity Markers in Patients With First-episode Conversive Motor Disorder
Lead Sponsor:
Centre Hospitalier Universitaire de Nīmes
Conditions:
Conversion Disorder
Eligibility:
All Genders
18-65 years
Brief Summary
Conversion disorders, also called "dissociative disorders" (ICD-10), or "functional neurological disorders" (DSM-5), are a common condition, with a prevalence of 1-10% in medical and surgical inpatien...
Detailed Description
This project is an ancillary study carried out from the cohort of patients included in the HYCORE protocol "PET-Scan evaluation of metabolic abnormalities associated with the clinical evolution at 6 m...
Eligibility Criteria
Inclusion
- The patient must have given free and informed consent and signed the consent.
- Patient must be enrolled in or a beneficiary of a health insurance plan.
- Patient's age is \> 18 and ≤ 65 years.
- Patient meets DSM-IV criteria for conversive motor disorder (with paralysis, motor weakness, or abnormal movements) evolving for less than 1 month and is euthymic (HAMD score \< or =7 assessed by a psychiatrist).
- First episode (incident case)
- The last symptom is less than one month old.
- The patient is not on neuroleptics.
Exclusion
- Subject is participating in another study
- Subject is in an exclusion period determined by a previous study
- Subject is under court protection, guardianship, or conservatorship
- The subject refuses to sign the consent form
- It is impossible to provide the subject with informed information
- The patient is pregnant, parturient, or nursing
- Specialized neurological clinical examination and brain and spinal cord MRI reveal organic neurological damage
- The subject presents a HAMD score \>7
- Subject has a current manic or hypomanic episode, a current diagnosis of substance abuse/dependence (excluding tobacco), a lifetime diagnosis of schizophrenia, or a chronic neurological condition (active epilepsy, stroke, brain tumor)
- Suicidal or high-risk subjects (assessed using the MINI)
- The subject has a contraindication to the performance of a PET scan
- Patient is on neuroleptic medication at inclusion
- The last symptom is more than one month old
- The patient has already had an episode (prevalent case).
Key Trial Info
Start Date :
April 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 15 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05305014
Start Date
April 1 2022
End Date
April 15 2022
Last Update
November 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ismael CONEJERO
Nîmes, Choisir Une Région, France, 30029